Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE  BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
...the design and manufacturing of circuits at nanosc...f the frontier fields in new material science and ...these devices often is accompanied by new discover...are of extremely small dimensions. Understanding t...me has enabled researchers to study the possibilit...
...tek Biosciences,Corporation (Nasdaq: MATK ) annou...ing Canaccord Adams Healthy Living Conference bein...l in Boston, MA. Pete Buzy, CFO and,David Abramson...rn Time on,Wednesday, October 15., A live audio w...:, http://www.newswire.ca/en/webcast/viewEvent.cgi...
...sualty incidents --,such as terrorist attacks, pan...thquakes or hurricanes -- raise the life-and-death...equate to provide treatment for all who,need it. O...ators for,people requiring respiratory support., ... know that mass,casualty events could mean that:, ...
Other Biology Technology:A new material could act as a nanofridge for microchips 2Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents 2Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents 3
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6New Insights Could Help Shield Babies From Diarrhea Bug 51939 1New Insights Could Help Shield Babies From Diarrhea Bug 51939 2Blacks Have Highest Obesity Rates in U S 51937 1Blacks Have Highest Obesity Rates in U S 51937 2Blacks Have Highest Obesity Rates in U S 51937 3Arcadian Chairman and Chief Executive Officer Robert Fahlman to Present at Focus on Healthcare Conference in New York City 51935 1
...Amsterdam, 12 November 2008. - Elsevier, a leading...formation products and services, announced today t...Life Sciences ( http://www.elsevier.com/locate/nj...ricultural Sciences (KLV), starting in 2009 with V...f Life Sciences , published since 1952, is the qua...
...A rapid, climate change-induced northern migration...s announced Tues. Nov. 11 during opening day prese...iodiversity, Ciudad de las Artes y las Ciencias, i...species of marine macroalgae spread at 50 km per d... invasive terrestrial plants. The difference may ...
...WEST LAFAYETTE, Ind. - A Purdue University researc...on of the virus that causes SARS and could lead to...SARS in 2003 led to hundreds of deaths and thousan...nt," said Arun Ghosh, the Purdue professor that le...urrently a threat, there is the concern that SARS ...
Other Biology News:Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 2Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 3Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told 4Purdue researcher invents molecule that stops SARS 2Purdue researcher invents molecule that stops SARS 3
Mouse Oligodendrocyte Differentiation Kit from R&D Systems
Goat Anti-VAP-1 (S-13) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
...atoms at the 3, 3', 4, and 4' positions. It is int...tification of Prostaglandin E2 (PGE2) by GC- or LC...looxygenase products of arachidonic acid and one o... activity influences inflammation, fertility and p...
Site-directed Mutagenesis from Exon BioSystems
Biology Products: